Profile data is unavailable for this security.
About the company
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
- Revenue in USD (TTM)4.02bn
- Net income in USD-31.56m
- Incorporated1994
- Employees18.60k
- LocationCharles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
- Phone+1 (781) 222-6000
- Fax+1 (978) 988-5665
- Websitehttps://www.criver.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | 0.00 | -269.44m | 4.48bn | 69.00 | -- | 4.13 | -- | -- | -3.75 | -3.75 | 0.00 | 13.60 | 0.00 | -- | -- | 0.00 | -26.06 | -36.86 | -27.01 | -38.94 | -- | -- | -- | -- | -- | -- | 0.0317 | -- | -- | -- | -66.09 | -- | -- | -- |
| Alkermes Plc | 1.51bn | 355.65m | 4.75bn | 1.80k | 13.59 | 3.14 | 12.39 | 3.14 | 2.12 | 2.10 | 9.00 | 9.17 | 0.7198 | 1.24 | 4.74 | 840,983.30 | 16.91 | 6.99 | 21.53 | 9.14 | 84.42 | 83.31 | 23.49 | 10.68 | 2.92 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Nuvalent Inc | 0.00 | -300.86m | 5.72bn | 162.00 | -- | 5.66 | -- | -- | -4.40 | -4.40 | 0.00 | 14.09 | 0.00 | -- | -- | 0.00 | -33.17 | -25.32 | -35.27 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Ionis Pharmaceuticals Inc | 717.25m | -458.03m | 6.33bn | 1.07k | -- | 13.31 | -- | 8.83 | -2.99 | -2.99 | 4.69 | 2.99 | 0.2572 | 0.5042 | 31.99 | 670,956.10 | -16.43 | -11.71 | -18.33 | -13.72 | 98.53 | 98.42 | -63.86 | -44.15 | 9.62 | -- | 0.7245 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
| Legend Biotech Corp (ADR) | 728.30m | -218.15m | 6.38bn | 2.70k | -- | 6.26 | -- | 8.76 | -1.19 | -1.19 | 3.97 | 5.53 | 0.4296 | 9.46 | 396.25 | 280,116.50 | -12.87 | -30.18 | -15.01 | -36.54 | 65.51 | -- | -29.95 | -154.41 | 5.07 | -6.95 | 0.2628 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Madrigal Pharmaceuticals Inc | 317.38m | -391.59m | 6.68bn | 528.00 | -- | 9.39 | -- | 21.04 | -18.04 | -18.04 | 14.56 | 32.03 | 0.3053 | 0.3831 | -- | 601,104.20 | -37.67 | -68.48 | -43.57 | -85.32 | 96.61 | -- | -123.38 | -876.55 | 5.58 | -- | 0.1424 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Revolution Medicines Inc | 0.00 | -697.51m | 6.88bn | 616.00 | -- | 3.31 | -- | -- | -3.99 | -3.99 | 0.00 | 11.16 | 0.00 | -- | -- | 0.00 | -32.64 | -28.38 | -34.69 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.00 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -31.56m | 7.37bn | 18.60k | -- | 2.31 | 19.73 | 1.83 | -0.65 | -0.65 | 78.33 | 65.04 | 0.5113 | 8.07 | 5.21 | 216,268.70 | -0.2963 | 5.12 | -0.3424 | 6.01 | 34.69 | 36.56 | -0.5796 | 9.47 | 1.16 | 3.81 | 0.4368 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| BIO-TECHNE Corp | 1.21bn | 131.65m | 8.13bn | 3.10k | 63.19 | 4.03 | 33.51 | 6.72 | 0.8204 | 0.8204 | 7.54 | 12.87 | 0.4506 | 2.19 | 5.20 | 389,925.50 | 4.91 | 9.42 | 5.22 | 10.04 | 66.39 | 67.29 | 10.89 | 21.41 | 2.58 | 46.27 | 0.1405 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Blueprint Medicines Corp | 562.12m | -155.73m | 8.28bn | 682.00 | -- | 24.18 | -- | 14.74 | -2.46 | -2.46 | 8.77 | 5.30 | 0.5032 | 0.901 | 8.04 | 866,132.50 | -13.94 | -23.15 | -17.53 | -26.82 | 96.48 | 96.65 | -27.70 | -75.50 | 2.75 | -- | 0.5313 | -- | 104.04 | 50.22 | 86.77 | -- | -19.87 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 8.60bn | 12.00 | -- | 1,046.73 | -- | -- | -0.0087 | -0.0087 | 0.00 | 0.0166 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| Medpace Holdings Inc | 2.16bn | 416.39m | 8.93bn | 5.90k | 23.71 | 15.58 | 20.04 | 4.14 | 13.10 | 13.10 | 67.79 | 19.94 | 1.17 | -- | 7.47 | 365,522.00 | 22.55 | 16.40 | 51.59 | 29.77 | 31.51 | 29.51 | 19.31 | 16.75 | -- | -- | 0.00 | 0.00 | 11.84 | 19.62 | 43.07 | 32.19 | 15.33 | -- |
| Exact Sciences Corp | 2.83bn | -1.02bn | 10.12bn | 6.90k | -- | 4.22 | -- | 3.58 | -5.50 | -5.50 | 15.26 | 12.71 | 0.468 | 5.74 | 10.87 | 409,873.60 | -16.87 | -11.29 | -18.71 | -12.38 | 69.02 | 71.21 | -36.06 | -30.90 | 2.38 | -173.16 | 0.494 | -- | 10.37 | 25.78 | -403.97 | -- | 0.9474 | -- |
Data as of Jun 30 2025. Currency figures normalised to Charles River Laboratories International Inc's reporting currency: US Dollar USD
47.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 5.91m | 11.56% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 3.88m | 7.59% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 2.91m | 5.69% |
| UBS Securities LLCas of 31 Mar 2025 | 2.31m | 4.53% |
| Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 2025 | 1.95m | 3.81% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 1.90m | 3.72% |
| Allspring Global Investments LLCas of 31 Mar 2025 | 1.76m | 3.44% |
| Geode Capital Management LLCas of 31 Mar 2025 | 1.26m | 2.47% |
| Impactive Capital LPas of 31 Mar 2025 | 1.21m | 2.37% |
| Ariel Investments LLCas of 31 Mar 2025 | 1.10m | 2.15% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
